Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph No
Lymph nodes are one of the most important components of the human immune system, and superficial lymph node enlargement lacks specificity. Ultrasound examination has been widely used in the diagnosis of lymph node lesions and is of great significance in distinguishing between benign and malignant. However, the two-dime
| Condition(s) | Lymphadenopathy, Lymphnode Metastasis, Lymphoma, Lymphatic Tuberculosis |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Lymph nodes are one of the most important components of the human immune system, and superficial lymph node enlargement lacks specificity. Ultrasound examination has been widely used in the diagnosis of lymph node lesions and is of great significance in distinguishing between benign and malignant. However, the two-dimensional and Doppler ultrasound features of different types of lymph node lesions overlap and intersect, and the blood flow perfusion information of lymph nodes can provide more information for differentiation. At present, the widely used contrast-enhanced ultrasound is easier to evaluate blood flow perfusion and can display small blood vessels smaller than 100 microns. The diagnostic accuracy of cervical lymph nodes using contrast-enhanced ultrasound is 80-90%. However, curre |
| Who can participate | Inclusion Criteria: * (1)suggested abnormal lymph nodes indicated by ultrasonography; (2) Patients scheduled for lymph nodes puncture or fine needle aspiration or surgery; (3) Age greater than or equal to 18 years old. Exclusion Criteria: * (1) Pregnant and lactating women; (2)pathological results not indicating benign or malignant lymph nodes; (3) history of chemotherapy or radiotherapy ; (4) History of allergies to eggs, milk, and ultrasound contrast agents; (5) Patients with acute coronary syndrome, severe pulmonary hypertension, or acute respiratory distress syndrome. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Peking University Third Hospital |
| Locations | Beijing, Beijing Municipality, China |
| Start date | 2024-10-23 |
| NCT ID | NCT07155954 |
| Official listing | https://clinicaltrials.gov/study/NCT07155954 |